Cienfuegos, December 21 (RHC)-- The Cuban medication CIMAvax-EGF against advanced lung cancer has begun its final stage of clinical trials in the province of Cienfuegos.
Developed by the Havana-based Molecular Immunology Center, the Cuban vaccine is the first registered therapeutic treatment of its kind that generates antibodies against the patient's epidermal growth factor (EGF).
The antibodies generated by the drug inhibit and stop the proliferation of tumor cells, thus stabilizing the pathology, increasing survival and ostensibly improving the patients' quality of life.
Clinical trial lead researcher Yoana Herrera Leyva said that the aim is to assess the response of patients to high and normal doses of the vaccine, in order to customize the treatment.
Cuban Lung Cancer Vaccine Begins Final Stage of Clinical Trials
Matérias relacionadas
Comentários
Deixe um comentário
Todos os campos são requeridos
Reproduzindo agora
El Mundo de la Filatelia
A seguir
- La Música en el Cine Latinoamericano
- Boletín Resumen
- Esperanto
Mais vistas
- Cuba ajuda países a suprir a falta de recursos humanos na área de saúde
- Cuba Saúde 2025, um evento em Havana para o bem-estar universal
- Feira Internacional de Saúde consolida o papel de Cuba na biotecnologia
- Luto oficial em Cuba pelo falecimento de Francisco
- Católicos de Cuba expressam pesar pela morte de Francisco